| (Values in U.S. Thousands) | Apr, 2025 | Jan, 2025 | Oct, 2024 | Apr, 2024 | Jan, 2024 |
| Sales | 701 | 372 | 429 | 559 | 537 |
| Sales Growth | +88.62% | -13.41% | -23.18% | +4.09% | -8.96% |
| Net Income | -66 | -304 | -347 | -759 | -862 |
| Net Income Growth | +78.26% | +12.17% | +54.34% | +11.97% | -288.12% |
Universal Ibogaine Inc (IBO.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.
Fiscal Year End Date: 07/31